SCHEMBL6767486

SCHEMBL6767486

O=C(O)c1ccc2c(c1)C(=O)N(Cc1ccc(Cl)cc1)C2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HDAC1 Q13547 7/20 0.48
HDAC6 Q9UBN7 5/20 0.48
HDAC4 P56524 4/20 0.48
HPGD P15428 1/20 0.46
ENPP2 Q13822 1/20 0.45
SRD5A1 P18405 1/20 0.43
SRD5A2 P31213 1/20 0.43
MAPK1 P28482 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA9 Q16790 1/20 0.43
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42
PRKAB1 Q9Y478 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065219 0.89 HDAC1 (0.59) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL12446495 0.89 HDAC1 (0.49) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL6764235 0.86 MAPK1 (0.48) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL12446493 0.85 HDAC1 (0.52) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL7984900 0.85 L3MBTL1 (0.53) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL6762069 0.84 CA1 (0.49) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL1065002 0.80 MEN1 (0.69) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL12363333 0.79 KMT2A (0.47) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL2019162 0.79 HDAC1 (0.56) MEN1KMT2AHDAC1HDAC6HDAC4
SCHEMBL23784314 0.78 HDAC1 (0.46) MEN1KMT2AHDAC1HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US claimed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US disclosed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis MMP13, MMP11, MMP9 MEN1 2463/4885KMT2A 4041/4885HDAC1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.